Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:LUCD News 22 January 2026

PAVmed stock dips premarket after VA contract drives near-double rally in PAVM shares

PAVmed stock dips premarket after VA contract drives near-double rally in PAVM shares

PAVmed shares dropped 3.4% to $11.64 in premarket trading Thursday, following a 94.7% surge the previous session after its Lucid Diagnostics unit secured a U.S. Veterans Affairs contract for the EsoGuard test. Lucid shares fell 10.6% premarket. Investors are seeking details on test rollout and volumes. PAVmed recently completed a 1-for-30 reverse stock split to meet Nasdaq requirements.
22 January 2026
··

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop